Trial Profile

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II/III Study of the Safety and Efficacy of ADC189 Tablets in the Treatment of Influenza A Virus Infection/Influenza B Virus Infection in Adolescents and Adults

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 24 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ADC 189 (Primary)
Indications Influenza A virus infections; Influenza B virus infections; Influenza virus infections
Focus Adverse reactions; Therapeutic Use
Sponsors Jiaxing AnDiCon Biotech

21 Jan 2025 Status changed from recruiting to completed.
06 May 2024 According to Simcere Pharmaceutical Media Release,Primary endpoint (the severity of influenza) has been met.
06 May 2024 According to Simcere Pharmaceutical Media Release,Primary endpoint(the safety of study drug) has been met.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com